Aclaris Therapeutics Inc (ACRS) is Initiated by Leerink Partners to Outperform, Price Target at $54

Aclaris Therapeutics Inc (ACRS) was Initiated by Leerink Partners to “Outperform” and the brokerage firm has set the Price Target at $54. Leerink Partners advised their investors in a research report released on Nov 29, 2016.

Many Wall Street Analysts have commented on Aclaris Therapeutics Inc. Aclaris Therapeutics Inc was Initiated by JMP Securities to “Mkt Outperform” on Sep 30, 2016.

In a different news, on Oct 28, 2016, Kamil Ali-jackson (Chief Legal Officer) sold 3,912 shares at $21.83 per share price. According to the SEC, on Oct 13, 2015, Albert Cha (director) purchased 454,545 shares at $11.00 per share price.

Aclaris Therapeutics Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate A-101 is being developed as an in-office treatment for seborrheic keratosis a non-cancerous skin tumor as well as for other cutaneous indications such as common warts. In addition the Company is engaged in developing a portfolio of Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions. The Company’s products A-201 and A-301 are indicated for the treatment of alopecia areata. The Company’s A-101 product is entering Phase III clinical trials for the treatment of seborrheic keratosis and Phase II clinical trials for the treatment of common warts. The Company’s A-201 and A-301 products are in pre- clinical stage.

Aclaris Therapeutics Inc

Leave a Reply

Aclaris Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aclaris Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.